According to Nature magazine, Chinese scientists are currently developing a new generation of anti-obesity medications that not only promote weight loss but also improve heart and liver health, while aiding in the management of type 2 diabetes.
اضافة اعلان
In a recent study, researchers tested a new drug called Ecnoglutide, which demonstrated significant effects: individuals with obesity lost an average of 13.8 kilograms over a period of 48 weeks, and reduced more than 5% of their body mass.
Scientists explained that Ecnoglutide mimics the action of the GLP-1 hormone, which regulates appetite and blood sugar levels. Unlike existing medications such as Semaglutide, the new drug targets different molecular pathways, which may not only enhance weight loss but also help maintain the results after treatment ends. Clinical trials also showed improvements in indicators linked to cardiovascular disease risk and fatty liver disease.
In parallel, Chinese pharmaceutical companies are testing new formulations of weight-loss medications that offer additional benefits for the heart and liver. These include bi-weekly injections and oral medications, with some drugs combining the effects of three hormones to target fat and sugar metabolism, as well as liver function. One such medication is UBT251, which has been approved for international marketing by pharmaceutical giant Novo Nordisk.
Researchers emphasize that the development of these drugs is no coincidence. Obesity and diabetes are among the most pressing health issues in China and India, and these new medications may pave the way for targeted treatments that take into account the unique metabolic profiles of Asian populations and the comorbidities associated with obesity in the region.
— Lenta.ru
